Paxlovid not linked to Covid-19 rebound, FDA says ahead of meeting to consider drug’s full approval

Paxlovid not linked to Covid-19 rebound, FDA says ahead of meeting to consider drug’s full approval

As the US Food and Drug Administration’s independent advisers prepare to discuss Thursday the full approval of Pfizer’s Covid-19 antiviral, Paxlovid, agency experts said this week that clinical trial data shows that it is safe and effective for treatment of mild to moderate illness in high-risk adults.